Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > New tranche of went thru
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by MetzGERon May 05, 2022 1:05pm
93 Views
Post# 34659159

RE:RE:RE:RE:RE:RE:New tranche of went thru

RE:RE:RE:RE:RE:RE:New tranche of went thru I am Not clever enough to understand this.

You know what i think about this Directors...

after als we have to See that Replicel got a Big Deal with Shiseido For RCH-01. If RepliCels product would be a Scam then Shiseido wouldnt do a Second Dose finding Trial with multiple injections.i mean it isnt a Small Company it is Shiseido the 4th biggest cosmetic company with the best of the best top scientist. They would give so much faith und the product of it is cr.ap. The Stock Price is down because The development of this product Takes to much Time. I Hope we Are the ones which earn a lot For our patience But we will see. Lee Buckler is the Last in which we should Trust. It is all about Shiseido 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities